609 related articles for article (PubMed ID: 30808672)
1. AKT as a Therapeutic Target for Cancer.
Song M; Bode AM; Dong Z; Lee MH
Cancer Res; 2019 Mar; 79(6):1019-1031. PubMed ID: 30808672
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
4. Akt as a therapeutic target in cancer.
Steelman LS; Stadelman KM; Chappell WH; Horn S; Bäsecke J; Cervello M; Nicoletti F; Libra M; Stivala F; Martelli AM; McCubrey JA
Expert Opin Ther Targets; 2008 Sep; 12(9):1139-65. PubMed ID: 18694380
[TBL] [Abstract][Full Text] [Related]
5. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Pandurangan AK
Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
[TBL] [Abstract][Full Text] [Related]
6. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
7. Akt in cancer: Mediator and more.
Revathidevi S; Munirajan AK
Semin Cancer Biol; 2019 Dec; 59():80-91. PubMed ID: 31173856
[TBL] [Abstract][Full Text] [Related]
8. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
[TBL] [Abstract][Full Text] [Related]
10. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment.
Ahmad A; Biersack B; Li Y; Kong D; Bao B; Schobert R; Padhye SB; Sarkar FH
Anticancer Agents Med Chem; 2013 Sep; 13(7):1014-24. PubMed ID: 23272911
[TBL] [Abstract][Full Text] [Related]
12. AKT in cancer: new molecular insights and advances in drug development.
Mundi PS; Sachdev J; McCourt C; Kalinsky K
Br J Clin Pharmacol; 2016 Oct; 82(4):943-56. PubMed ID: 27232857
[TBL] [Abstract][Full Text] [Related]
13. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
15. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
18. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
19. Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line.
Zhou Z; Tang M; Liu Y; Zhang Z; Lu R; Lu J
Anticancer Drugs; 2017 Apr; 28(4):446-456. PubMed ID: 28125432
[TBL] [Abstract][Full Text] [Related]
20. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]